Viral Antigen Ingredients TRIZ Cases

A bacteriophage composition targets oncogenic bacteria to lyse carcinogenic cells.

A PEP005 combination composition reactivates latent HIV through synergistic signaling activation.

An immunogenic composition comprising specific antigenic peptides induces broadly neutralizing antibodies targeting diverse HIV-1 isolates.

A solid-phase diagnostic method employs spatially separated NS1 and envelope protein antigens to detect IgM and IgG antibodies in patient samples.

Attenuated IBDV activates host interferon pathways to treat nidovirus infections while avoiding drug toxicity and safety concerns.

Self-assembling nanoparticles display antigens in a unidirectional, repetitive manner using a split-protein conjugation system.

Tromethamine adjusts pH with temperature to bind viruses in cyclodextrin, eliminating freeze-thaw damage and glycerol irritation.

A recombinant African swine fever virus vaccine deletes virulence genes to induce protective immunity without causing clinical disease in swine.

A selective estrogen receptor modulator mediates spike protein interference with estrogen signaling, reducing side effects while maintaining vaccine efficacy.

A live attenuated HIV vaccine uses blank codon suppression to introduce unnatural amino acids into the viral genome.

Targeting conserved HIV gp41 and gp120 epitopes with binding proteins prevents viral entry, addressing the lack of clinically approved neutralizing antibodies.

Tapered conduit membranes balance immunoprotection and insulin release by varying pore sizes across segmented layers.

A recombinant baculovirus vector delivers HPV antigens to stimulate robust immune responses.

G1P[8] rotavirus vaccine composition induces protective immune response through neutralizing antibodies, resolving inconsistency from variant mixtures.

Engineered immunogenic compositions mimic BG18 binding properties to induce broadly neutralizing antibodies, overcoming low naive B cell priming frequency.

A recombinant nucleic acid sequence encodes synthetic antibodies that bind and neutralize the hepatitis B virus.

Fusion protein combines gp41 sequence with trimerization motif and immunoenhancer to boost antibody affinity.

TK and IL18bp deletions in recombinant swinepox vectors stabilize foreign gene expression, resolving replication-efficiency trade-offs.

Segmenting the flexible V3 tip reduces structural disorder, enabling crystallization and directing immune responses toward diverse HIV strains.

Attenuated African Swine Fever viruses protect pigs from infection while enabling serological differentiation between vaccinated and infected animals.

Codon shuffled helper genes prevent wild-type reversion during vaccine vector manufacturing.

Proteolipid vehicles with FAST proteins resolve low intracellular DNA delivery efficiency by mediating membrane fusion for robust immune responses.

Intramuscular injection into the dorsal muscle avoids organ injury and handling stress while maintaining antibody production.

Combining S, Pre-S1, and Pre-S2 antigens in a single formulation generates broad-spectrum antibodies that neutralize multiple HBV genotypes and escape variants.

Segmented V2 loop epitopes overcome gp120 targeting failures by inducing broadly neutralizing antibodies.

Segmenting binding and toxic functions reduces off-target toxicity while delivering CD8+ T-cell epitopes.

HPV vaccine reduces skin cancer size and recurrence by boosting immune response against viral proteins without adjuvants.

Mutant IL-2 immunoconjugates reduce vascular leak syndrome by binding activated T cells while sparing regulatory populations.

Multi-component HPV vaccine couples L2 peptide with T helper epitope and Toll-like receptor agonist to stimulate robust antibody response.

Recombinant HIV envelope proteins use specific amino acid substitutions to stabilize the trimeric conformation and increase soluble yield.

Replacing non-essential viral genes with immunogen sequences simplifies construction and boosts success rates for bivalent vaccines.

Replacing nuclear quantification with fluorescence detection enables high-throughput screening of neutralizing antibodies.

Segmenting envelope proteins into specific peptides detects divergent EIAV and NEV infections that standard p26 recombinant tests miss.

Anti-idiotype antibodies mimic conserved HIV gp120 epitopes, evoking neutralizing immunity while bypassing viral escape mutations.

Simultaneous APC induction and T cell priming in one culture system reduces process time while maintaining reliable activation signals.

Enriched anti-Zika human immunoglobulin preparation neutralizes the virus to prevent transmission to the fetus and reduce congenital defects.

Segmented gp120 epitopes into a scaffolded chimera to elicit neutralizing antibodies against diverse HIV subtypes.

Polypeptide mutations stabilize the HCMV pentamer complex, improving thermostability and epitope accessibility to overcome glycan shielding.

Alpha-gal epitope compositions recruit immune cells to accelerate tissue repair in diabetic and aged subjects with impaired healing.

Cell squeeze platforms deliver antigens into PBMCs to resolve low efficacy of pure cell populations.

Lentiviral vectors transduce CD4 T cells with genetic elements to inhibit CCR5 production and target HIV RNA sequences.

Targeting conserved epitopes shared across HIV, SIV, and FIV overcomes viral mutation evasion to ensure consistent cellular immunity.

Swinepox viruses with foreign genes inserted into the IL18bp gene provide stable expression and improved immunogenicity for PCV2 vaccines.

Free amino acids buffer the basic environment of lipoidal excipients, preventing RNA hydrolysis while maintaining delivery effectiveness.

A five-primer isothermal amplification system detects nucleic acid sequences using strand-displacing enzymes at a fixed temperature.

A chimeric PCV1-2b vaccine incorporates the PCV2b capsid gene into a non-pathogenic PCV1 backbone to induce protective immunity.

A dissolvable microneedle patch delivers immune stimulants directly into the skin using biodegradable polymer structures.

Removing the N-terminal segment of the HPV 18 L1 protein enables high-yield E. coli expression and native VLP formation.